Kineta Inc (KA) - Company Net Income

KA (Kineta) - company brandmark

Kineta, Inc. (KA) currently reports a net income level of 0.00 according to the historical metric on the GURU.Markets chart. This trend reflects the scalability of the pharmaceutical business, where patents enable the generation of global revenue with low production costs. Demand for combating tumor resistance is immense, although sales remain dependent on testing. Prospects are further bolstered by the development of new immunotherapeutic molecules with a long asset value cycle.

KA (Kineta, Inc.) Net Profit history from 04/28/2023 to 09/28/2024

Analytical breakdowns and data insights for company Kineta (KA)

- market price and analyst price targets:
Price Rate Chart Kineta Corp|KA - Consensus Target
- market capitalization indicators:
Market Value Kineta Corp|KA - Real Price to Acquire Entire Company
- balance sheet equity data:
Accounting Value of a Share Kineta|KA - Book Capitalization|Market Capitalization to Book Value kinetabio.com|KA - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Kineta, Inc.|KA - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Kineta Inc|KA - Company Total Debt|Debts to Book Capitalization Kineta Corp|KA - Company Long-Term Debt|Company Short-Term Indebtedness Kineta|Immediate Liquidity kinetabio.com
- net income and valuation multiples indicators:
KA - Net Income
Summary company analysis:Kineta, Inc.
Core merchandise of Kineta Bio

Kineta, Inc. (KA) strategic alliances with biotech laboratories to develop cancer immunotherapy establish the foundation for capitalizing on future medical breakthroughs. By analyzing the company's net profit levels, investors assess current market dynamics of daily financial results rather than past reports, enabling them to determine the balance between asset value and the fundamental stability of quotes amid competition.

Main competitors

Annual Net Income NantKwest IBRX|Net Income IMCR|Company Net Income januxrx.com JANX|Net Income RCUS (Arcus Biosciences)|ZYME (Zymeworks Inc) - Final Profit|Net Profit TNGX (Tango Pharma)|Net Financial Result Iovance Corp (IOVA)|IMTX - Company Net Income|xencor.com (XNCR) - Net Income|Compass Therapeutics, Inc. (CMPX) - Company Net Income|Net Income Replimune Group Inc|Net Income LYEL|Net Profit Innate Pharma S.A|Company Net Income Pyxis Oncology, Inc. (PYXS)|cgen.com - Company Profit|Company Net Income IO Biotech IOBT|Sutro Biopharma Inc. (STRO) - Company Net Income|INKT: Net Income|Annual Net Income Werewolf Therapeutics (HOWL)|IMMX (immixbio.com) - Net Income|ALXO: Profit After Payment of Taxes|CUE (Cue Biopharma) - Net Profit|PDSB: Final Profit|Net Profit SONN|MAIA - Company Net Income|Company Net Income Liminatus Pharma LIMN|Final Profit LVTX|NextCure - Net Profit|LPTX - Net Profit|intensitytherapeutics.com (INTS) - Company Net Income|Profit After Tax SNSE (Sensei Biotherapeutics, Inc.)|Net Income TOVX|Company Net Income Gritstone Bio GRTS|Company Net Income NexImmune (NEXI)|Net Profit turnstonebio.com (TSBX)|Net Profit VCNX (Vaccinex, Inc)|Net Financial Result Harpoon Therapeutics Corp (HARP)